RBC Capital raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $95 and keeps an Outperform rating on the shares. The firm cites the company’s better-than-expected Q1 results along with raised 2026 revenue outlook given that the FDA recently granted priority review for Tryngolza, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
- Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
- Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
- Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook
- Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)